Takashi Tsukamoto, PhD
Highlights
Languages
- English
Gender
MaleJohns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Takashi Tsukamoto
Professional Titles
- Director, Medicinal Chemistry, Johns Hopkins Drug Discovery Program
Primary Academic Title
Professor of Neurology
Background
Takashi Tsukamoto, Ph.D. is a Professor of Neurology at Johns Hopkins University and the Director of Medicinal Chemistry at Johns Hopkins Drug Discovery Program. Dr. Tsukamoto received his Ph.D. degree in Chemistry from Tokyo Institute of Technology and pursued postdoctoral studies in the Department of Medicinal Chemistry at the University of Michigan. Prior to joining Johns Hopkins in 2009, Dr. Tsukamoto has held a variety of research positions in the pharmaceutical industry including Guilford Pharmaceuticals, MGI Pharma, and the Eisai Research Institute. During the course of his career, he has served as a lead medicinal chemist in a number of drug discovery projects exploring new therapeutics for neurological disorders and cancer. At the Johns Hopkins Drug Discovery Program, Dr. Tsukamoto leads a team of medicinal chemists involved in the design and synthesis of small molecules of therapeutic significance in various projects.
Centers and Institutes
Additional Academic Titles
Professor of Pharmacology and Molecular Sciences
Contact for Research Inquiries
855 North Wolfe Street, Suite 231
Baltimore, MD 21205-1503
Phone: (410) 614-0982
ttsukamoto@jhmi.edu
Research Interests
Drug Discovery
Research Summary
Medicinal chemistry in the areas of neurological disorders and cancer
Selected Publications
δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors. Ferraris DV, Majer P, Ni C, Slusher CE, Rais R, Wu Y, Wozniak KM, Alt J, Rojas C, Slusher BS, Tsukamoto T. J Med Chem. 2014 Jan 9;57(1):243-7. doi: 10.1021/jm401703a. Epub 2013 Dec 27. PMID: 24354364
Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T. J Med Chem. 2014 Mar 27;57(6):2582-8. doi: 10.1021/jm401856k. Epub 2014 Feb 24. PMID: 24520856
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Exp Hematol. 2014 Apr;42(4):247-51. doi: 10.1016/j.exphem.2013.12.001. Epub 2013 Dec 11. PMID: 24333121
Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Rojas C, Raje M, Tsukamoto T, Slusher BS. Eur J Pharmacol. 2014 Jan 5;722:26-37. doi: 10.1016/j.ejphar.2013.08.049. Epub 2013 Oct 31. PMID: 24184669
MrgC agonism at central terminals of primary sensory neurons inhibits neuropathic pain. He SQ, Li Z, Chu YX, Han L, Xu Q, Li M, Yang F, Liu Q, Tang Z, Wang Y, Hin N, Tsukamoto T, Slusher B, Tiwari V, Shechter R, Wei F, Raja SN, Dong X, Guan Y. Pain. 2014 Mar;155(3):534-44. doi: 10.1016/j.pain.2013.12.008. Epub 2013 Dec 11. PMID: 24333779
Courses & Syllabi
- Introduction to Drug Discovery Research, ME:200.704
- Drug Discovery Case Studies, ME:200.707
Honors
- Tejima Award for Distinguished Ph.D. Thesis, Tokyo Institute of Technology, 1/1/94
- Ichikizaki Fund for Young Chemists, Chemical Society of Japan, 1/1/92
- Ikueikai Scholarship, 1/1/92
Lectures & Presentations
- Design, Synthesis and Biological Activity of NAALADase Inhibitors, Pacifichem 2000, Honolulu, Hawaii, 1/14/00
- Academic Drug Discovery Efforts in USA, RaQualia Pharma, Aichi, Japan, 1/30/09
- Brain, Drugs, and Chemistry, K.I Chemical Research Institute, Shizuoka, Japan, 1/29/09
- Career in Chemistry, Challenges and Opportunities, College of Notre Dame of Maryland, Baltimore, Maryland, 1/29/10
- Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia, Nagoya University School of Medicine, Aichi, Japan, 1/22/10
- Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia, University of Tokushima School of Medicine, Tokushima, Japan, 1/11/11
- Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia, Otsuka Pharmaceutical, Tokyo, Japan, 1/12/11
- Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia, Asubio Pharma, Tokyo, Japan, 1/12/11
- Discovery of D-amino acid oxidase Inhibitors as new therapeutics for schizophrenia, National Center of Neurology and Psychiatry, Tokyo, Japan, 1/3/10
- Drug Discovery in Academia, Eisai Tsukuba Research Laboratories, Ibaraki, Japan, 1/26/10
- Drug discovery research at the intersection of chemistry and biology, Morgan State University, Baltimore, Maryland, 1/22/11
- Drug discovery research at the intersection of chemistry and biology, CCBC Society of STEM Scholars, Baltimore, Maryland, 1/16/11
- Drug discovery research at the intersection of chemistry and biology, STEM Scholars STEP Up Summer Program, Harford Community College, Belair, Maryland, 1/1/11
- Inhibition of Glutamate Carboxypeptidase II: A novel approach to reduce glutamate excitotoxicity, International Conference on Protease Inhibitors, Nagoya, Japan, 1/13/03
- Medicinal chemistry of D-amino acid oxidase inhibitors, Chiba University School of Medicine, Chiba, Japan, 1/16/10
- Novel therapeutics for schizophrenia, Joint meeting of the Johns Hopkins University Alliance for Science and Technology Development and the University of Maryland., Baltimore, Maryland, 1/4/10
- Role of NAAG in Neuroprotection, First International Symposium on N-Acetylaspartate (Canavan Disease), Bethesda, MD, 1/14/04
- The Johns Hopkins Brain Science Institute Translational Program: Discovering Treatments for Brain Disorders, Vanderbilt University, Nashville, TN, 1/10/09
- The regioselective nucleophilic reactions of 4,4-difluoroglutamic acid diester and synthetic applications, 210th ACS National Meeting, Chicago, IL, 1/20/95
- Therapeutic Utility of GCP II (NAALADase) Inhibitors in Neurodegenerative diseases, GTCbio 2nd Annual conference on Therapeutic Strategies against Neurodegenerative Conditions (TSANC), Washington, DC, 1/19/06
Memberships
- American Chemical Society
Professional Activities
- Bioorganic Medicinal Chemistry, Reviewer
- Bioorganic Medicinal Chemistry Letters, Reviewer
- Chemistry and Intellectual Property Brain Science Institute, Director, 1/1/09
- Chesapeake Chemist, Editor-in-Chief, 1/1/11
- Incentive Mentoring Program, Mentor, 1/1/10
- Journal of Biological Chemistry, Reviewer
- Journal of Medicinal Chemistry, Reviewer
- Journal of Organic Chemistry, Reviewer
- Maryland Section of the American Chemical Society, Chair, 1/1/11
- Medicinal Chemistry Eisai Research Institute, Director, 1/1/08 - 1/1/09
- Medicinal Chemistry Guilford Pharmaceuticals Inc., Principal Scientist I, 1/1/05 - 1/1/05
- Medicinal Chemistry MGI Pharma, Director, 1/1/06 - 1/1/08
- Open Medicinal Chemistry Journal, Reviewer
Additional Training
University of Michigan, Ann Arbor, Michigan, 1997, Medicinal Chemistry